# Cibinqo (abrocitinib) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/abrocitinib

> The FDA approved Cibinqo (abrocitinib), sponsored by PFIZER INC (PFE), on January 14, 2022 for to treat refractory, moderate-to-severe atopic dermatitis.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Cibinqo (abrocitinib) FDA approved?

Yes. The FDA approved Cibinqo (abrocitinib), sponsored by PFIZER INC (PFE), on January 14, 2022 for to treat refractory, moderate-to-severe atopic dermatitis. FDA novel drug approvals: "Cibinqo | abrocitinib | 1/14/2022 | To treat refractory, moderate-to-severe atopic dermatitisDrug Trials Snapshot" [Calendar and source filings](https://sec-api.dev/pdufa/abrocitinib)

Source: FDA novel drug approvals, https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022 (retrieved 2026-11-16). Last confirmed 2026-11-16T22:20:01.192Z. Cite: https://sec-api.dev/pdufa/abrocitinib#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Cibinqo (abrocitinib) |
| Codes | PF-04965842 |
| Sponsor | PFIZER INC (PFE) https://sec-api.dev/companies/pfe/catalysts |
| Indications | To treat refractory, moderate-to-severe atopic dermatitis, [Dermatitis, Atopic](https://sec-api.dev/indications/dermatitis-atopic), [Eczema](https://sec-api.dev/indications/eczema), [Atopic Dermatitis](https://sec-api.dev/indications/atopic-dermatitis) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### January 14, 2022: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: To treat refractory, moderate-to-severe atopic dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA novel drug approvals: "Cibinqo | abrocitinib | 1/14/2022 | To treat refractory, moderate-to-severe atopic dermatitisDrug Trials Snapshot" https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2022
- openFDA Drugs@FDA: "NDA213871 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20220114, review_priority PRIORITY; sponsor_name PFIZER; product CIBINQO (ABROCITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213871%22

### February 9, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213871 SUPPL-1 (Efficacy): submission_status AP, submission_status_date 20230209, review_priority PRIORITY; sponsor_name PFIZER; product CIBINQO (ABROCITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213871%22

### December 14, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "NDA213871 SUPPL-4 (Efficacy): submission_status AP, submission_status_date 20231214, review_priority STANDARD; sponsor_name PFIZER; product CIBINQO (ABROCITINIB)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA213871%22

### December 22, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Dermatitis, Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT03422822 (Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-12-22 (ACTUAL); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT03422822

### May to Aug 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Eczema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06807268 (A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-02 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06807268

### May 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Eczema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06807268 (A Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-05-02 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT06807268

### Apr to Jul 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07823595 (Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-04-10 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07823595

### April 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Atopic Dermatitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07823595 (Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age): Overall Status NOT_YET_RECRUITING; Phase PHASE3; Primary Completion 2029-04-10 (ESTIMATED); Lead Sponsor Pfizer." https://clinicaltrials.gov/study/NCT07823595

## Same indication

- [ATI-045](https://sec-api.dev/pdufa/ati-045) (ACRS)
- [Barzolvolimab](https://sec-api.dev/pdufa/barzolvolimab) (CLDX)
- [Evo756, dose 1](https://sec-api.dev/pdufa/evo756) (EVMN)
- [GHZ339](https://sec-api.dev/pdufa/ghz339) (NVS)
- [GIA632](https://sec-api.dev/pdufa/gia632) (NVS)
- [GSK1070806](https://sec-api.dev/pdufa/gsk1070806) (GSK)
- [JNJ-95475939](https://sec-api.dev/pdufa/jnj-95475939) (JNJ)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)
- [KT-621](https://sec-api.dev/pdufa/kt-621) (KYMR)
- [Lebrikizumab](https://sec-api.dev/pdufa/lebrikizumab) (LLY)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [PF-08049820](https://sec-api.dev/pdufa/pf-08049820) (PFE)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Roflumilast cream 0.3%](https://sec-api.dev/pdufa/roflumilast-cream-0-3) (ARQT)
- [JAKAFI (ruxolitinib)](https://sec-api.dev/pdufa/ruxolitinib) (INCY)
- [Ruxolitinib cream](https://sec-api.dev/pdufa/ruxolitinib-cream) (INCY)
- [Sar444656 (kt-474)](https://sec-api.dev/pdufa/sar444656-kt-474) (SNY)
- [Tapinarof cream, 1%](https://sec-api.dev/pdufa/tapinarof-cream-1) (OGN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)

Calendar months: [May 2027](https://sec-api.dev/fda-calendar/2027-05)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/abrocitinib.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Cibinqo (abrocitinib) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/abrocitinib

```bibtex
@misc{secapidev_pdufa_abrocitinib_20261116,
  title        = {Cibinqo (abrocitinib) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/abrocitinib}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_abrocitinib_20261116","title":"Cibinqo (abrocitinib) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/abrocitinib","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
